Research Research Areas Research Groups Selected Publications Selected Projects Open Science
Laboratories Core Facilities Booking system RICAIP Testbed Brno Industry Cooperation
Education PhD School Postdoc Programme Seminar Series Summer School Internships Secondary Teachers
Career Training Jobs MSCA–PF HRS4R Award Alumni Network Welcome Office Innovation Accelerator
About Us News Events People Organisational Structure Scientific Evaluation To Download Press and Media Contacts
CZ
Home Research Selected Publications Three-year follow-up of patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) receiving ibrutinib plus bendamustine and rituximab (BR) versus placebo plus BR: an update of the HELIOS study
Share Share Share

Three-year follow-up of patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) receiving ibrutinib plus bendamustine and rituximab (BR) versus placebo plus BR: an update of the HELIOS study

LEUKEMIA & LYMPHOMA

Hallek, M; Fraser, G; Cramer, P; Demirkan, F; Silva, RS; Grosicki, S; Janssens, A; Pristupa, A; Mayer, J; Dilhuydy, MS; Loscertales, J; Bartlett, N; Avigdor, A; Rule, S; Sun, S; Mahler, M; Phelps, C; Salman, M; Howes, A; Chanan-Khan, A, 2017: Three-year follow-up of patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) receiving ibrutinib plus bendamustine and rituximab (BR) versus placebo plus BR: an update of the HELIOS study. LEUKEMIA & LYMPHOMA 58, p. 192 - 194

CEITEC authors: